NCT00220272View on ClinicalTrials.gov

Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

183

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
Parkinson Disease
Interventions
DRUG

SR57667B

Trial Locations (7)

Unknown

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Helsinki

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Gouda

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Geneva

Sanofi-Aventis Administrative Office, Guildford Surrey

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00220272 - Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease | Biotech Hunter | Biotech Hunter